Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-04-28 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
华融证券股份有限公司关于云南生物谷药业股份有限公司2021年度募集资金存放与实际使用情况的专项核查报告
Regulatory Filings
2022-04-28 Chinese
2021年募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company through stock issuance. It references regulatory guidelines from the China Securities Regulatory Commission and the Beijing Stock Exchange, and includes detailed financial figures on fundraising amounts, usage, balances, and compliance with relevant laws. The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds, which aligns with a capital/financing update rather than a full annual or interim financial report. It is not an announcement of a report publication but the report itself, given the length (5672 characters) and detailed financial data. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2022-04-28 Chinese
关于确认2021年度日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the confirmation of 2021 annual related party transactions by the company. It includes details about the transactions, related parties, pricing policies, and board meeting resolutions approving these transactions. The document is relatively short (2890 characters) and focuses on disclosure of related party transactions rather than presenting comprehensive financial statements or audit results. It does not contain full financial data or detailed financial performance analysis. Therefore, it is not an Annual Report (10-K), Audit Report (AR), or Interim Report (IR). It is a regulatory announcement about related party transactions, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories.
2022-04-28 Chinese
关于云南生物谷药业股份有限公司2021 年度控股股东及其关联方资金占用的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation regarding the use of funds by the controlling shareholder and its related parties for the fiscal year 2021. It references an audit conducted by a certified public accounting firm, including details about the audit report with a reservation opinion issued on April 27, 2022. The document includes financial data related to the controlling shareholder's fund occupation and compliance with regulatory disclosure requirements. It is not the full annual report but a specific audit-related disclosure focusing on a particular issue (fund occupation by controlling shareholders). The document length is 1413 characters, which is relatively short but contains substantive financial and audit information, not merely an announcement or certification. Therefore, it fits best under Audit Report / Information (AR) as it is a standalone audit-related report on a specific matter, not the full annual report or a simple announcement. FY 2021
2022-04-28 Chinese
云南生物谷药业股份有限公司2021年度募集资金年度存放与使用情况鉴证报告
Regulatory Filings
2022-04-28 Chinese
第四届董事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the fourth board meeting of Yunnan Biological Valley Pharmaceutical Co., Ltd. It includes information about the meeting date, attendees, and the voting results on various agenda items such as the 2021 board work report, independent director work report, financial statements, budget, profit distribution, auditor reappointment, amendments to the company charter, and other corporate governance matters. The document references multiple other announcements and reports that are disclosed separately on the Beijing Stock Exchange website. The content is focused on board meeting decisions and approvals rather than the full text of any financial report or annual report itself. This type of document fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length (5835 characters) and detailed meeting minutes support this classification rather than a brief announcement or a full annual report.
2022-04-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.